9 Meters Biopharma Competitors

Phibro Animal Health (NASDAQ:PAHC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Valuation and Earnings

This table compares Phibro Animal Health and 9 Meters Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Phibro Animal Health has higher revenue and earnings than 9 Meters Biopharma.

Institutional and Insider Ownership

50.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 19.9% of 9 Meters Biopharma shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 26.7% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Phibro Animal Health and 9 Meters Biopharma, as reported by MarketBeat.

Phibro Animal Health presently has a consensus target price of $21.50, suggesting a potential downside of 12.39%. 9 Meters Biopharma has a consensus target price of $5.00, suggesting a potential upside of 334.78%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Phibro Animal Health.

Profitability

This table compares Phibro Animal Health and 9 Meters Biopharma's net margins, return on equity and return on assets.

Summary

Phibro Animal Health beats 9 Meters Biopharma on 8 of the 11 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and Enanta Pharmaceuticals' top-line revenue, earnings per share and valuation.

9 Meters Biopharma has higher earnings, but lower revenue than Enanta Pharmaceuticals.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Enanta Pharmaceuticals, as provided by MarketBeat.com.

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Enanta Pharmaceuticals has a consensus price target of $65.2857, suggesting a potential upside of 33.92%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares 9 Meters Biopharma and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Summary

9 Meters Biopharma beats Enanta Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and Arcturus Therapeutics' top-line revenue, earnings per share and valuation.

Arcturus Therapeutics has higher revenue and earnings than 9 Meters Biopharma.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Arcturus Therapeutics, as provided by MarketBeat.com.

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Arcturus Therapeutics has a consensus price target of $70.6667, suggesting a potential upside of 90.99%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Arcturus Therapeutics.

Profitability

This table compares 9 Meters Biopharma and Arcturus Therapeutics' net margins, return on equity and return on assets.

Summary

9 Meters Biopharma beats Arcturus Therapeutics on 6 of the 11 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and Akero Therapeutics' top-line revenue, earnings per share and valuation.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Akero Therapeutics, as provided by MarketBeat.com.

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Akero Therapeutics has a consensus price target of $57.2857, suggesting a potential upside of 106.36%. Given 9 Meters Biopharma's higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Akero Therapeutics.

Profitability

This table compares 9 Meters Biopharma and Akero Therapeutics' net margins, return on equity and return on assets.

Summary

9 Meters Biopharma beats Akero Therapeutics on 4 of the 7 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and ESSA Pharma's top-line revenue, earnings per share and valuation.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and ESSA Pharma, as provided by MarketBeat.com.

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. ESSA Pharma has a consensus price target of $28.80, suggesting a potential upside of 1.52%. Given 9 Meters Biopharma's higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than ESSA Pharma.

Profitability

This table compares 9 Meters Biopharma and ESSA Pharma's net margins, return on equity and return on assets.

9 Meters Biopharma (NASDAQ:NMTR) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Earnings and Valuation

This table compares 9 Meters Biopharma and Annexon's top-line revenue, earnings per share and valuation.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 91.2% of Annexon shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Annexon, as provided by MarketBeat.com.

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Annexon has a consensus price target of $34.3333, suggesting a potential upside of 37.72%. Given 9 Meters Biopharma's higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Annexon.

Profitability

This table compares 9 Meters Biopharma and Annexon's net margins, return on equity and return on assets.

Summary

9 Meters Biopharma beats Annexon on 5 of the 7 factors compared between the two stocks.